Hamad Alsaykhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hamad Alsaykhan has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Elsayed A. Elmorsy
Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah 52571, Saudi Arabia; Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
4 shared publications - Mostafa M. Khodeir
Department of Pathology, College of medicine, Qassim University, Buraidah, Saudi Arabia
4 shared publications - Sameh Saber
Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, 11152, Egypt
4 shared publications - Ahmed Y. Kira
Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt
3 shared publications - Manal Mohamed Hatem
Department of Anatomy and Histology, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia
3 shared publications - Mohammed Alorini
Department of Pathology, College of Medicine, Qassim University, Buraidah 51452, Saudi Arabia
3 shared publications
Latest Publications
- 8 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 268
pH-Responsive Chitosan-Coated Spanlastic Nanovesicles for Enhanced Lung-Targeted Delivery of Brilliant Blue G in Acute Lung Injury
Acute lung injury (ALI) involves alveolar–capillary barrier disruption, inflammatory amplification, oxidative stress, and loss of alveolar architectu
- 8 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 268
pH-Responsive Chitosan-Coated Spanlastic Nanovesicles for Enhanced Lung-Targeted Delivery of Brilliant Blue G in Acute Lung Injury
Acute lung injury (ALI) involves alveolar–capillary barrier disruption, inflammatory amplification, oxidative stress, and loss of alveolar architectu
- 24 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1016, 178602
Reprogramming lysosomal–purinergic crosstalk governs the synergistic attenuation of NLRP3 inflammasome activation by cyclodextrin–P2X7 blockade in diabetic rats
- 24 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1016, 178602
Reprogramming lysosomal–purinergic crosstalk governs the synergistic attenuation of NLRP3 inflammasome activation by cyclodextrin–P2X7 blockade in diabetic rats